About Choice Therapeutics
Choice Therapeutics is a Healthcare company based in Wrentham (United States) founded in 2006, and was acquired by Alliqua in May 2014. Wound care products for burns and surgical infections are manufactured. Choice Therapeutics has raised $1.95 million across 2 funding rounds from investors including Alliqua. Its chief executive, as recorded, is Jim Hutchens. The company was acqui-hired. Its focus areas include Life Sciences, Wound Care and Drugs. Its competitors include Claris Bio, Tempo Therapeutics and Solsys Medical; 3 of its 3 listed competitors have raised funding.
Company details
Choice Therapeutics manufactures wound care products for burns, advanced wound care, and surgical site infections. It offers TheraBond 3D Contact Dressings used as contact layers for wounds; TheraBond 3D Wraps used as contact dressings configured in a bandage wrap design; and TheraBond 3D Island Dressings for incisions. TheraBond 3D provides infection prevention and protection in a variety of post-op scenarios such as Cardiothoracic surgery, Vascular surgery, Orthopedic surgery, Foot and ankle surgery and others. As of May 5, 2014, Choice Therapeutics operates as a subsidiary of Alliqua Biomedical.
- Headquarters Wrentham, United States
- Stage Acquired
- SectorsHealthcare
- Website choicetherapeutics.com
- Social LinkedIn
- Acquired by Alliqua (May 2014)
Funding Insights of Choice Therapeutics
Choice Therapeutics has successfully raised a total of $1.95M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $582 thousand completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.95M
- Total Rounds 2
- Last Round Seed — $582,000
- First Round $1.37M
(Jul 2009)
All 2 funding rounds of Choice Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2011 | $582,000 | Seed | – | – | – |
| Jul 2009 | $1.37M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Choice Therapeutics
Choice Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Alliqua.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Wound care solutions through transdermal drug delivery | 1997 | alliqua.com | Yardley, United States |
Investor details for Choice Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Choice Therapeutics
1 people are tracked at Choice Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jim Hutchens | CEO | Leadership |
Complete people profiles for Choice Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Choice Therapeutics
4 dated milestones of Choice Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Choice Therapeutics is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Seed, of $582K.
- Exit Acquired by Alliqua.
Competitors of Choice Therapeutics
Choice Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Claris Bio, Tempo Therapeutics and Solsys Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| clarisbio.com | 2018 | Jersey, United States | $44.5M | Topical formulations for corneal wounds, ulcers, and scars are developed. | ||
| tempothera.com | 2014 | San Diego, United States | $20.17M | Regenerative biomaterials for wounds are developed using particle technology. | ||
| solsysmedical.com | 1999 | Norfolk, United States | $29.55M | Human skin allografts and dressings for wound care are supplied. |
Detailed competitors of Choice Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Wound Care
3 companies that operate in the same segment as Choice Therapeutics (Wound Care) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | 35 | ||
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | USD 418.63 M | 837 | ||
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Choice Therapeutics
Choice Therapeutics was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Choice Therapeutics is headquartered in Wrentham, United States. It is registered at Wrentham, Massachusetts, United States.
Jim Hutchens is the CEO of Choice Therapeutics, as recorded in our data.
Choice Therapeutics is a funded company, having raised a total of $1.95M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.37M, raised on Jul 2009.
Choice Therapeutics manufactures wound care products for burns, advanced wound care, and surgical site infections. It offers TheraBond 3D Contact Dressings used as contact layers for wounds; TheraBond 3D Wraps used as contact dressings configured in a bandage wrap design; and TheraBond 3D Island Dressings for incisions. TheraBond 3D provides infection prevention and protection in a variety of post-op scenarios such as Cardiothoracic surgery, Vascular surgery, Orthopedic surgery, Foot and ankle surgery and others. As of May 5, 2014, Choice Therapeutics operates as a subsidiary of Alliqua Biomedical.
Choice Therapeutics's top competitors include Tempo Therapeutics, Solsys Medical and Claris Bio.
Choice Therapeutics has 1 investor. Key investors include Alliqua.
Yes. Choice Therapeutics was acquired by Alliqua in May 2014.